ClinicalTrials.Veeva

Menu
A

ASST Fatebenefratelli Sacco | Luigi Sacco University Hospital - Gastroenterology and Digestive Endoscopy Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Esketamine
ANX007
Filgotinib
Ritonavir
Bictegravir
Enoxaparin
Lenacapavir
Nirmatrelvir
BUCCALIN®
JNJ-81201887

Parent organization

This site is a part of ASST Fatebenefratelli Sacco

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 19 total trials

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to...

Active, not recruiting
Geographic Atrophy
Drug: Vonaprument
Other: Sham Administration
Status recently updated

The goal of this clinical trial is to assess if BUCCALIN® works In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIS). It will...

Not yet enrolling
Enrolling
Lower Respiratory Tract Infection (LRTI)
Respiratory Infection
Drug: BUCCALIN®
Other: Placebo

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting
HIV-1-infection
Drug: Stable Baseline Regimen
Drug: Bictegravir
Locations recently updated

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

A
Janssen (J&J Innovative Medicine) logo
Pfizer logo
A
A
Gilead Sciences logo
S
Takeda logo
U
D

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems